À compter du 1er décembre 2023, l’accès à POEMs et à Essential Evidence Plus ne fera plus partie des avantages offerts aux membres de l’AMC.
Question clinique
Can lopinavir-ritonavir improve outcomes for patients hospitalized with COVID-19?
L’Essentiel
A randomized trial of 199 patients found no evidence of benefit for lopinavir-ritonavir in patients with COVID-19. A larger trial is needed. 2b
Référence
Plan de l'etude: Randomized controlled trial (nonblinded)
Financement: Self-funded or unfunded
Cadre: Outpatient (primary care)
Sommaire
Research Brief #6 (Cao, 2020) In this open-label trial, researchers in Wuhan enrolled patients hospitalized with COVID-19 and oxygen saturation of 94% or less on room air. They randomized the patients to receive standard care (n = 100) or standard care plus an HIV-medication called lopinavir-ritonavir (Kaletra; 400 mg/ 100 mg; n = 99) twice a day for 14 days. They found no statistically significant difference in the duration of illness. Although the patients treated with lopinavir-ritonavir had 5.8% fewer deaths, this was not statistically significant. But in order to detect this difference a study would need more than 800 patients in each group. Stay tuned - hopefully, this will be studied further.
Reviewer
Henry C. Barry, MD, MS
Professor
Michigan State University
East Lansing, MI